Chiara Vagaggini, Debora Petroni, Ilaria D'Agostino, Federica Poggialini, Chiara Cavallini, Annarita Cianciusi, Annalisa Salis, Lucia D'Antona, Valeria Francesconi, Fabrizio Manetti, Gianluca Damonte, Francesca Musumeci, Luca Menichetti, Elena Dreassi, Anna Carbone, Silvia Schenone
Glioblastoma multiforme (GBM) is one of the most aggressive malignancies with a high recurrence rate and poor prognosis. Theranostic, combining therapeutic and diagnostic approaches, arises as a successful strategy to improve patient outcomes through personalized medicine. Src is a non-receptor tyrosine kinase (nRTK) whose involvement in GBM has been extensively demonstrated. Our previous research highlighted the effectiveness of the pyrazolo[3,4-d]pyrimidine SI306 and its more soluble prodrug CMP1 as Src inhibitors both in in vitro and in vivo GBM models...
February 2024: Drug Development Research